Literature DB >> 16497578

The development and impact of tuberculosis vaccines.

Douglas Young1, Christopher Dye.   

Abstract

Vaccination is expected to make a major contribution to the goal of eliminating tuberculosis worldwide by 2050. But developing a new effective vaccine will require innovation in scientific research, a proactive approach to clinical trials of new vaccine candidates, and application of vaccines as part of an integrated approach to disease control.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497578     DOI: 10.1016/j.cell.2006.02.013

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  32 in total

1.  Immune gene networks of mycobacterial vaccine-elicited cellular responses and immunity.

Authors:  Dan Huang; Liyou Qiu; Richard Wang; Xioamin Lai; George Du; Probhat Seghal; Yun Shen; Lingyun Shao; Lisa Halliday; Jeff Fortman; Ling Shen; Norman L Letvin; Zheng W Chen
Journal:  J Infect Dis       Date:  2006-11-22       Impact factor: 5.226

2.  Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain.

Authors:  D Aguilar; E Infante; C Martin; E Gormley; B Gicquel; R Hernandez Pando
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Planning to improve global health: the next decade of tuberculosis control.

Authors:  Dermot Maher; Chris Dye; Katherine Floyd; Andrea Pantoja; Knut Lonnroth; Alasdair Reid; Eva Nathanson; Thad Pennas; Uli Fruth; Jane Cunningham; Heather Ignatius; Mario C Raviglione; Irene Koek; Marcos Espinal
Journal:  Bull World Health Organ       Date:  2007-05       Impact factor: 9.408

4.  Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon.

Authors:  Teresa M Wozniak; Bernadette M Saunders; Anthony A Ryan; Warwick J Britton
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

5.  Synthesis of hydroxyphthioceranic acid using a traceless lithiation-borylation-protodeboronation strategy.

Authors:  Ramesh Rasappan; Varinder K Aggarwal
Journal:  Nat Chem       Date:  2014-07-27       Impact factor: 24.427

Review 6.  Challenges and future in vaccines, drug development, and immunomodulatory therapy.

Authors:  Heather M Kling; Gerard J Nau; Ted M Ross; Thomas G Evans; Krishnendu Chakraborty; Kerry M Empey; JoAnne L Flynn
Journal:  Ann Am Thorac Soc       Date:  2014-08

7.  IFN-beta improves BCG immunogenicity by acting on DC maturation.

Authors:  Elena Giacomini; Maria Elena Remoli; Valérie Gafa; Manuela Pardini; Lanfranco Fattorini; Eliana M Coccia
Journal:  J Leukoc Biol       Date:  2008-12-04       Impact factor: 4.962

8.  Interactions of attenuated Mycobacterium tuberculosis phoP mutant with human macrophages.

Authors:  Nadia L Ferrer; Ana B Gomez; Olivier Neyrolles; Brigitte Gicquel; Carlos Martin
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

9.  Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis.

Authors:  Julio C C Lorenzi; Ana P F Trombone; Carolina D Rocha; Luciana P Almeida; Ricardo L Lousada; Thiago Malardo; Isabela C Fontoura; Renata A M Rossetti; Ana F Gembre; Aristóbolo M Silva; Celio L Silva; Arlete A M Coelho-Castelo
Journal:  BMC Biotechnol       Date:  2010-10-20       Impact factor: 2.563

10.  IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia.

Authors:  Helena del Corral; Sara C París; Nancy D Marín; Diana M Marín; Lucelly López; Hanna M Henao; Teresita Martínez; Liliana Villa; Luis F Barrera; Blanca L Ortiz; María E Ramírez; Carlos J Montes; María C Oquendo; Lisandra M Arango; Felipe Riaño; Carlos Aguirre; Alberto Bustamante; John T Belisle; Karen Dobos; Gloria I Mejía; Margarita R Giraldo; Patrick J Brennan; Jaime Robledo; María P Arbeláez; Carlos A Rojas; Luis F García
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.